In the evolving landscape of bladder cancer (BCa) immunotherapy, this commentary offers a critical and timely reflection on a recent review that we published previously on targeting innate lymphoid cells (ILCs) in BCa.
No takes yet. Share an insight, caveat, or question.
Hassouneh et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: